查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842340

美国甲状腺癌诊断市场：市场规模、份额、趋势分析（按癌症类型、技术、最终用途和地区划分）、细分市场预测（2025-2033 年）

U.S. Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer (Papillary Carcinoma, Follicular Carcinoma), By Technique (Imaging, Biopsy), By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

据估计，2024 年美国甲状腺癌诊断市值为 10.2 亿美元，预计到 2033 年将达到 14.8 亿美元，2025 年至 2033 年的复合年增长率约为 4.30%。

美国的甲状腺癌诊断正在迅速发展，预计到2025年将新增44,020例病例，死亡2,290例。该疾病在女性中更为常见，通常在较年轻时确诊，且在黑人人群中的发生率较低。过去几十年，影像学检查导致的过度诊断使得甲状腺癌发生率持续上升，但自2014年以来，更严格的诊断标准已使发病率每年下降2%。基因组学、人工智慧辅助影像学和分子检测技术的进步，使得精准医疗成为可能，从而减少了过度治疗，并改善了侵袭性亚型的治疗效果。

在美国，甲状腺癌的诊断正迅速发展，受到发病率趋势、风险因素以及分子检测技术进步的影响。美国癌症协会预测，2025年，美国新患者（男性12,670例，女性31,350例），死亡2,290例，且确诊年龄通常较年轻（平均51岁）。女性患病的可能性约为男性的三倍，而黑人患病的可能性比其他族裔低40%至50%。过去40年间，甲状腺癌的发生率显着上升，这主要是由于高灵敏度影像检查的广泛应用，这些检查能够检测出体积小、局限性强的肿瘤，且这些肿瘤的生存率极高，但其中很大一部分是过度诊断。自2014年以来，更严格的诊断标准减少了过度诊断，使得甲状腺癌的发生率每年下降2%，而死亡率自2009年以来一直保持稳定。

与这些趋势相伴随的是，一些重要的病因发现也逐渐浮现。历史上，儿童时期的辐射暴露是唯一可改变的风险因素，但现在肥胖已被公认为一个重要的促成因素。此外，内分泌干扰物和甲状腺功能障碍在疾病发展中的作用也正在被探索。重要的是，基因和分子谱分析已经识别出一些具有预后意义的突变，例如BRAFV600E、RAS、RET和NTRK，这些突变为精准治疗提供了标靶。这些发现不仅加深了我们对疾病的理解，而且透过将分子检测和新一代次世代定序仪整合到切片检查评估中，实现了对良性和恶性结节的更佳鑑别，从而重塑了诊断方法。

目录

第一章 分析方法和范围

第二章执行摘要

第三章美国甲状腺癌诊断市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国甲状腺癌诊断市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析

第四章美国甲状腺癌诊断市场：按癌症类型分類的商业分析

  • 癌症专属仪錶板
  • 甲状腺癌诊断市场：按癌症类型分類的波动分析
  • 美国甲状腺癌诊断市场规模及趋势分析（按癌症类型划分）（2021-2033 年）
  • 乳头状癌
  • 滤泡癌
  • 其他的

第五章美国甲状腺癌诊断市场：按技术分類的业务分析

  • 技术专用仪錶板
  • 甲状腺癌诊断市场：依技术分類的差异分析
  • 美国甲状腺癌诊断市场规模及技术趋势分析（2021-2033）
  • 血液检查
  • 影像
  • 切片检查
  • 其他的

第六章美国甲状腺癌诊断市场：按最终用途分類的业务分析

  • 按最终用户分類的仪表板
  • 甲状腺癌诊断市场：依最终用途分類的差异分析
  • 美国甲状腺癌诊断市场规模及趋势分析（按最终用途划分）（2021-2033 年）
  • 医院检查室
  • 癌症诊断中心
  • 研究所
  • 其他的

第七章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 主要企业热力图分析（2024 年）
  • 公司简介
    • Abbott
    • F.Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific, Inc.
    • Siemens Healthcare GmbH
    • Bio-Rad Laboratories, Inc.
    • GE HealthCare
    • Hologic, Inc.
    • Koninklijke Philips NV
    • Toshiba Corporation
    • Agilent Technologies, Inc.
    • Illumina, Inc.
Product Code: GVR-4-68040-728-1

Market Size & Trends:

The U.S. thyroid cancer diagnostics market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 1.48 billion by 2033, growing at a CAGR of around 4.30% from 2025 to 2033. Thyroid cancer diagnostics in the U.S. are rapidly evolving, with 2025 estimates projecting 44,020 new cases and 2,290 deaths. The disease is more common in women, often diagnosed at a younger age, and less prevalent among Black populations. While incidence rose for decades due to overdiagnosis from imaging, stricter criteria have reduced rates by 2% annually since 2014. Advances in genomics, AI-driven imaging, and molecular testing now enable precision medicine, reduce overtreatment, and improve outcomes for aggressive subtypes.

Thyroid cancer diagnostics in the United States are evolving rapidly, shaped by changing incidence trends, risk factors, and advances in molecular tools. In 2025, the American Cancer Society projects about 44,020 new cases (12,670 in men and 31,350 in women) and 2,290 deaths, with diagnosis typically occurring at a younger age (average 51 years). The disease is nearly three times more common in women than in men and is about 40-50% less common among Black populations compared to other groups. Over the past four decades, incidence rose dramatically, largely due to widespread use of sensitive imaging tests that detected small, localized tumors with excellent survival rates-many of which represented overdiagnosis. Since 2014, stricter diagnostic criteria have helped reduce overdiagnosis, leading to a 2% annual decline in incidence, while mortality has remained stable since 2009.

Key etiological insights have emerged alongside these trends. Historically, childhood radiation exposure was the only modifiable risk factor; however, obesity has now been recognized as a major contributor, though its biological mechanisms are not fully understood. Research is also examining the role of endocrine-disrupting chemicals and thyroid dysfunction in disease development. Importantly, genetic and molecular profiling has identified critical mutations-such as BRAFV600E, RAS, RET, and NTRK-that are both prognostic and predictive, offering targets for precision therapies. These discoveries have not only improved disease understanding but have also reshaped diagnostics by integrating molecular assays and next-generation sequencing into biopsy evaluation, allowing better differentiation between benign and malignant nodules.

U.S. Thyroid Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. thyroid cancer diagnostics market report based on cancer, technique, end use, and region:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
    • Papillary carcinoma
    • Follicular carcinoma
    • Others
  • Technique Outlook (Revenue, USD Million, 2021 - 2033)
    • Blood Test
    • Imaging
    • Biopsy
    • Others
  • End Use Indication Outlook (Revenue, USD Million, 2021 - 2033)
    • Hospital Laboratories
    • Cancer Diagnostic Centers
    • Research Institutes
    • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technique
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer Outlook
    • 2.2.2. Technique Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Thyroid Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Thyroid Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. U.S. Thyroid Cancer Diagnostics Market: Cancer Business Analysis

  • 4.1. Cancer Segment Dashboard
  • 4.2. Thyroid Cancer Diagnostics Market: Cancer Movement Analysis
  • 4.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Cancer, 2021 to 2033 (USD Million)
  • 4.4. Papillary carcinoma
    • 4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 4.5. Follicular carcinoma
    • 4.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Thyroid Cancer Diagnostics Market: Technique Business Analysis

  • 5.1. Technique Segment Dashboard
  • 5.2. Thyroid Cancer Diagnostics Market: Technique Movement Analysis
  • 5.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Technique, 2021 to 2033 (USD Million)
  • 5.4. Blood Test
    • 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.5. Imaging
    • 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.6. Biopsy
    • 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Thyroid Cancer Diagnostics Market: End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Thyroid Cancer Diagnostics Market: End Use Movement Analysis
  • 6.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
  • 6.4. Hospital Laboratories
    • 6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.5. Cancer Diagnostic Centers
    • 6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.6. Research Institutes
    • 6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Abbott
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. F.Hoffmann-La Roche Ltd.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Thermo Fisher Scientific, Inc.
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Siemens Healthcare GmbH
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Bio-Rad Laboratories, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. GE HealthCare
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Hologic, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Koninklijke Philips N.V.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Toshiba Corporation
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Agilent Technologies, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Illumina, Inc.
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Abbreviations
  • Table 2 U.S. Thyroid Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 3 U.S. Thyroid Cancer Diagnostics Market, By Technique, 2021 - 2033 (USD Million)
  • Table 4 U.S. Thyroid Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Thyroid Cancer Diagnostics Market: Market Outlook
  • Fig. 10 Thyroid Cancer Diagnostics Competitive Insights
  • Fig. 11 Parent Market Outlook
  • Fig. 12 Related/Ancillary Market Outlook
  • Fig. 13 Penetration and Growth Prospect Mapping
  • Fig. 14 Industry Value Chain Analysis
  • Fig. 15 Thyroid Cancer Diagnostics Market Driver Impact
  • Fig. 16 Thyroid Cancer Diagnostics Market Restraint Impact
  • Fig. 17 Thyroid Cancer Diagnostics Market Strategic Initiatives Analysis
  • Fig. 18 Thyroid Cancer Diagnostics Market: Cancer Movement Analysis
  • Fig. 19 Thyroid Cancer Diagnostics Market: Cancer Outlook and Key Takeaways
  • Fig. 20 Papillary Carcinoma Market Estimates and Forecast, 2021 - 2033
  • Fig. 21 Follicular Carcinoma Market Estimates and Forecast, 2021 - 2033
  • Fig. 22 Others Market Estimates and Forecast, 2021 - 2033
  • Fig. 23 Thyroid Cancer Diagnostics Market: Technique Movement Analysis
  • Fig. 24 Thyroid Cancer Diagnostics Market: Technique Outlook and Key Takeaways
  • Fig. 25 Blood Test Market Estimates and Forecast, 2021 - 2033
  • Fig. 26 Imaging Market Estimates and Forecast, 2021 - 2033
  • Fig. 27 Biopsy Market Estimates and Forecast, 2021 - 2033
  • Fig. 28 Others Market Estimates and Forecast, 2021 - 2033
  • Fig. 29 Thyroid Cancer Diagnostics Market: End Use Movement Analysis
  • Fig. 30 Thyroid Cancer Diagnostics Market: End Use Outlook and Key Takeaways
  • Fig. 31 Hospital Laboratories Market Estimates and Forecasts, 2021 - 2033
  • Fig. 32 Cancer Diagnostic Centers Market Estimates and Forecasts, 2021 - 2033
  • Fig. 33 Research Institutes Market Estimates and Forecasts, 2021 - 2033
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033
  • Fig. 35 U.S. Market Estimates and Forecasts, 2021 - 2033